Get the Stockscreener App
0.31
4.69%
-0.01
Quoin Pharmaceuticals Ltd Adr stock is traded at $0.31, with a volume of 702.84K.
It is down -4.69% in the last 24 hours and down -53.79% over the past month.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
See More
Previous Close:
$0.32
Open:
$0.31
24h Volume:
702.84K
Relative Volume:
0.22
Market Cap:
$2.62M
Revenue:
-
Net Income/Loss:
$-8.28M
P/E Ratio:
-0.0558
EPS:
-5.56
Net Cash Flow:
$-7.99M
1W Performance:
-8.41%
1M Performance:
-53.79%
6M Performance:
-45.99%
1Y Performance:
-90.87%
1-Day Range:
$0.30
$0.33
1-Week Range:
$0.295
$0.46
52-Week Range:
$0.2811
$6.18
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Company Profile
Name
Quoin Pharmaceuticals Ltd Adr
Sector
Industry
Phone
97299741444
Address
23 HATA'AS STREET, KFAR SABA
Compare QNRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNRX
Quoin Pharmaceuticals Ltd Adr
|
0.309 | 2.62M | 0 | -8.28M | -7.99M | -5.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.06 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.00 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.98 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.70 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Latest News
After Jumping 10.61% During The Past Week, Should You Still Buy Recursion Pharmaceuticals Inc (NASDAQ: RXRX)? - Marketing Sentinel
Beyond Inc (NYSE: BYON) Has Succeeded In Generating Interest In 2025, The Stock Is Up 87.02% Year-To-Date - Marketing Sentinel
Should You Expect A Quick Recovery From Personalis Inc (NASDAQ: PSNL) After -35.08% Decline From High? - Marketing Sentinel
Market cap of Captivision Inc [CAPT] reaches 33.99M – now what? - The DBT News
Citigroup lifts StoneCo Ltd [STNE] price estimate. Who else is bullish? - The DBT News
Quoin Pharmaceuticals launches Netherton awareness campaign - Investing.com India
Understanding QNRX’s financial ratios: A beginner’s guide - US Post News
Earnings call transcript: Quoin Pharmaceuticals Q4 2023 sees stock volatility - MSN
Quoin Pharma's Netherton Syndrome Treatment Shows Strong Results, Requires Continuous Use - StockTitan
Future Outlook And Stock Price Performance For Quoin Pharmaceuticals Ltd ADR (NASDAQ: QNRX) - Marketing Sentinel
Quoin reports progress in pediatric skin disorder study - Investing.com
PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials - GlobeNewswire Inc.
Quoin Pharmaceuticals reports positive trial results for skin treatment - Investing.com
Quoin reports positive results in Netherton Syndrome study - Investing.com
Quoin Pharmaceuticals CFO Dunn Gordon buys $54,999 in shares - Investing.com India
Quoin Pharmaceuticals CEO Michael Myers acquires $250,000 in shares By Investing.com - Investing.com South Africa
Quoin Pharmaceuticals director Anthony Culverwell buys $45,000 in shares - Investing.com India
Quoin Pharmaceuticals COO Denise Carter buys $250,000 in shares - Investing.com India
Quoin Pharmaceuticals COO Denise Carter buys $250,000 in shares By Investing.com - Investing.com South Africa
Quoin Pharmaceuticals director Anthony Culverwell buys $45,000 in shares By Investing.com - Investing.com South Africa
Quoin Pharmaceuticals CFO Dunn Gordon buys $54,999 in shares By Investing.com - Investing.com South Africa
Quoin Pharmaceuticals sets terms for public offering - Investing.com
Quoin Pharmaceuticals advances Netherton Syndrome study - Investing.com India
Quoin Pharmaceuticals amends shareholder rights, adjusts executive compensation - Investing.com India
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results - Yahoo Finance
Quoin Pharmaceuticals advances Netherton syndrome treatment trial - Investing.com
Quoin Pharmaceuticals granted extension to meet Nasdaq listing - Investing.com India
Quoin Pharmaceuticals expands UK clinical trials for rare disease - Investing.com
Quoin Pharmaceuticals sets date for 2024 shareholder meeting - Investing.com
Balance Sheet Insights: Quoin Pharmaceuticals Ltd ADR (QNRX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Quoin Pharmaceuticals CFO buys shares worth over $23,000 - Investing.com
Healthy Upside Potential: Quoin Pharmaceuticals Ltd ADR (QNRX) - SETE News
A closer look at QNRX’s price-to-free cash flow ratio - US Post News
Quoin Pharmaceuticals COO acquires $28,737 in company shares - Investing.com
Quoin Pharmaceuticals CEO acquires shares worth over $28k - Investing.com
Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Quotes, Forecast and News Summary - Benzinga
QNRX Stock Hits 52-Week Low at $0.57 Amid Market Challenges - Investing.com Australia
GLMD Stock Quote Price and Forecast - CNN
symbol__ Stock Quote Price and Forecast - CNN
Earnings call: Quoin Pharmaceuticals reports Q4 progress and outlook By Investing.com - Investing.com South Africa
Why Quoin Pharmaceuticals (QNRX) Shares Are Nosediving - Benzinga
Major Indexes Muted Following Strong Jobs Report - Schaeffers Research
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Myers Michael | Chief Executive Officer |
Dec 23 '24 |
Buy |
0.45 |
555,556 |
250,000 |
602,808 |
| Dunn Gordon | Chief Financial Officer |
Dec 23 '24 |
Buy |
0.45 |
122,221 |
54,999 |
151,077 |
| Culverwell Anthony James | Director |
Dec 23 '24 |
Buy |
0.45 |
100,000 |
45,000 |
100,317 |
| Dunn Gordon | Chief Financial Officer |
Sep 10 '24 |
Buy |
0.81 |
20,000 |
16,200 |
28,856 |
| Dunn Gordon | Chief Financial Officer |
Sep 09 '24 |
Buy |
0.79 |
8,856 |
7,005 |
8,856 |
| Carter Denise P. | Chief Operating Officer |
Sep 04 '24 |
Buy |
0.78 |
31,813 |
24,912 |
47,092 |
| Carter Denise P. | Chief Operating Officer |
Sep 03 '24 |
Buy |
0.65 |
5,922 |
3,825 |
15,279 |
| Myers Michael | Chief Executive Officer |
Sep 04 '24 |
Buy |
0.77 |
37,094 |
28,421 |
47,252 |
| Myers Michael | Chief Executive Officer |
Sep 03 '24 |
Buy |
0.62 |
800 |
495 |
10,158 |
| LANGER DENNIS | Director |
Jun 07 '24 |
Sale |
0.73 |
297 |
217 |
53 |
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):